Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Shanghai Apeiron Therapeutics Company Limited has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, so the docket includes repeated examiner and art-unit relationships.
LEESER, ERICH A is the busiest listed examiner, with 2 pending actions. That examiner handles the larger identified share of the docket, making consistency across those matters useful. The remaining action should be managed separately because it has a different examiner and art-unit assignment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEESER, ERICH A | 2 | 81.9% | +13.3% |
| ROMERO, KRISTEN WANG | 1 | 69.8% | +30.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19426142 | PRMT5 INHIBITORS AND METHODS OF USE | LEESER, ERICH A | — |
| 18925084 | PRMT5 INHIBITORS AND METHODS OF USE | LEESER, ERICH A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19426142 | PRMT5 INHIBITORS AND METHODS OF USE | LEESER, ERICH A | — |
| 18865349 | KINESIN KIF18A INHIBITOR AND USE THEREOF | ROMERO, KRISTEN WANG | — |
| 18925084 | PRMT5 INHIBITORS AND METHODS OF USE | LEESER, ERICH A | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19426142 | PRMT5 INHIBITORS AND METHODS OF USE | LEESER, ERICH A | 1622 | §102DP | Non-Final OA | — | Pending | Dec 19, 2025 |
| 18865349 | KINESIN KIF18A INHIBITOR AND USE THEREOF | ROMERO, KRISTEN WANG | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18925084 | PRMT5 INHIBITORS AND METHODS OF USE | LEESER, ERICH A | 1622 | §102Other | Non-Final OA | — | Pending | Oct 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Apeiron Therapeutics Company Limited has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Erich A Leeser has the most, with 2 of Shanghai Apeiron Therapeutics Company Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
